This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tasneen, R.
Right arrow Articles by Nuermberger, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tasneen, R.
Right arrow Articles by Nuermberger, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2008, p. 3664-3668, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00686-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of Tuberculosis {triangledown}

Rokeya Tasneen, Sandeep Tyagi, Kathy Williams, Jacques Grosset, and Eric Nuermberger*

Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland

Received 25 May 2008/ Returned for modification 28 July 2008/ Accepted 4 August 2008

PA-824 is in phase II clinical testing to treat tuberculosis. At a dose of 100 mg/kg of body weight, it has demonstrated bactericidal activity during the initial and continuation phases of treatment in a murine model of tuberculosis. In a prior study, substitution of PA-824 for isoniazid in the first-line regimen of rifampin, isoniazid, and pyrazinamide resulted in significantly lower CFU counts at 2 months and shorter time to culture-negative conversion. However, the study design prevented a rigorous assessment of the relapse rate after completion of therapy. The current experiment was designed to assess (i) the extent of the beneficial effect of substituting PA-824 for isoniazid in the first-line regimen, (ii) the influence of the PA-824 dose on the same effect, and (iii) the activity of each one-, two-, and three-drug combination of rifampin, PA-824, and pyrazinamide. Mice were infected by the aerosol route and initiated on treatment 14 days later with more than 7 log10 CFU per lung. Treatment with rifampin and pyrazinamide was more effective than treatment with rifampin, isoniazid, and pyrazinamide at reducing the lung CFU count, consistent with past evidence of isoniazid's antagonism in this model. The addition of PA-824 at 12.5 and 25 mg/kg/day did not increase the activity of rifampin plus pyrazinamide, but the addition of PA-824 at 50 and 100 mg/kg/day did increase the activity in a dose-dependent manner. The combination of rifampin, PA-824 (100 mg/kg), and pyrazinamide rendered all mice culture negative after 2 months of treatment and free of relapse after 4 months of treatment, while some mice receiving rifampin, isoniazid, and pyrazinamide remained culture positive and 15% relapsed after completing 4 months of treatment. The two-drug combination of PA-824 and pyrazinamide displayed synergistic activity that was equivalent to that of the standard first-line regimen. Together, these results support the evaluation of regimens based on the combination of rifampin, PA-824, and pyrazinamide in phase II clinical trials while demonstrating several potential pitfalls in the evaluation of new drug combinations in a murine model of tuberculosis.

* Corresponding author. Mailing address: Center for Tuberculosis Research, Johns Hopkins University, 1550 Orleans Street, Baltimore, MD 21231-1002. Phone: (410) 502-0580. Fax: (410) 614-8173. E-mail: enuermb{at}jhmi.edu

{triangledown} Published ahead of print on 11 August 2008.

Antimicrobial Agents and Chemotherapy, October 2008, p. 3664-3668, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00686-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sung, J. C., Garcia-Contreras, L., VerBerkmoes, J. L., Peloquin, C. A., Elbert, K. J., Hickey, A. J., Edwards, D. A. (2009). Dry Powder Nitroimidazopyran Antibiotic PA-824 Aerosol for Inhalation. Antimicrob. Agents Chemother. 53: 1338-1343 [Abstract] [Full Text]  
  • Yew, W. W., Leung, C. C. (2009). Update in Tuberculosis 2008. Am. J. Respir. Crit. Care Med. 179: 337-343 [Full Text]  
  • Nuermberger, E., Mitchison, D. A. (2009). Once-Weekly Treatment of Tuberculosis with the Diarylquinoline R207910: A Real Possibility. Am. J. Respir. Crit. Care Med. 179: 2-3 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»